1. Hedner T, Narkiewicz K, Kjeldsen SE. The evolution of ACE inhibition – a turning point in cardiovascular medicine. Blood Press Suppl 2007; 2: 5–6.
2. Fyhrquist F. Clinical pharmacology of the ACE inhibitors. Drugs 1986; 32 (Suppl. 5): 33–9.
3. Mackaness GB. The future of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1985; 7 (Suppl. 1): S30–4.
4. Kelbaek H, Agner E, Wroblewski H et al. Angiotensin converting enzyme inhibition at rest and during exercise in congestive heart failure. Eur Heart J 1993; 14 (5): 692–5.
5. Marzo A, Dal Bo L, Mazzucchelli P et al. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittelforschung 1999; 49 (12): 992–6.
6. Cushman DW, Wang FL, Fung WC et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmac 1989; 28: 115S–131S.
7. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press Suppl 2007; 2: 19–24.
8. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27 (3): 371–6.
9. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl 2007; 2: 13–8.
10. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press Suppl 2007; 2: 7–12.
11. Omboni S, Malacco E, Parati G. Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. Cardiovasc Ther 2009; 27 (4): 275–88. Epub 2009 Oct 13.
12. Mutolo D, Bongianni F, Evangelista S et al. Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits. J Cardiovasc Pharmacol Ther 2010; 15 (4): 384–92.
13. Steinberg D, Witztum JL. Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis? Do the Antioxidant Trials Conducted to Date Refute the Hypothesis? Circulation 2002; 105: 2107–11.
14. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000; 28 (12): 1815–26.
15. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 2004; 43 (2): 294–9.
16. Napoli C, Sica V, de Nigris F et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148 (1): e5.
17. Gómez-Roso M, Montero MJ, Carrón R, Sevilla MA. Cardiovascular changes in spontaneously hypertensive rats are improved by chronic treatment with zofenopril. Br J Pharmacol 2009; 158 (8): 1911–21.
18. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
19. Carnicelli V, Frascarelli S, Zucchi R. Effect of acute and chronic zofenopril administration on cardiac gene expression. Mol Cell Biochem 2011; 352 (1–2): 301–7.
20. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1–8.
21. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
22. Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party. Am J Cardiol 1991; 68 (14): 101D–10D.
23. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332 (2): 80–5.
24. Borghi C, Ambrosioni E; Surival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145 (1): 80–7.
25. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)–ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7–14.
26. Cominacini L, Pasini A, Garbin U et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15 (10 Pt 1): 891–5.

Е.Г.Силина, Л.А.Алексанян 

Кафедра клинической фармакологии, фармакотерапии и скорой медицинской помощи МГМСУ